Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.08 or 1.14% from the prior close of $7.02. The stock opened at $7.02 and touched ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Investing.com -- Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab ... of Chief Financial Officer Kimi Iguchi and laid off over 165 employees as part of a reorganization to focus on the launch of ...